SanBio Company Limited
Matters Concerning Business Plan and Growth Potential
SanBio Inc. presented a business plan aiming to become a global leader in brain regeneration by pioneering the world’s first brain regenerative medicine, Akougo®.
Key Figures
- Capital: 8,375 million yen
- Number of Employees: 33 consolidated, 33 non-consolidated (as of January 31, 2026)
- Main Product: Brain regenerative medicine SB623 (Akougo®)
AI要約
Business Overview and Vision
SanBio Inc. has developed Akougo®, the world’s first brain regenerative medicine targeting chronic phase motor paralysis resulting from traumatic brain injury, which received conditional and time-limited approval in Japan in July 2024. The company’s mission is to become a global leader in brain regeneration by delivering value to patients and stakeholders through the development of regenerative medicine products.
Business Model and Pipeline
The company engages in research, development, manufacturing, and sales of cell therapies, primarily targeting central nervous system disorders. Its main product is SB623 (Akougo®), with development underway for treatments for a range of conditions including chronic phase traumatic brain injury, cerebral infarction, cerebral hemorrhage, and age-related macular degeneration. Clinical trials at various phases are ongoing, aiming to obtain approvals in the U.S. and Japan.
SanBio Inc.
Company overview · Stock price · Financial data · All IR
